中国再次肾脏移植临床诊疗指南(2023版)  

Clinical management guideline for kidney re-transplantation in China(2023 edition)

作　　者：中华医学会器官移植学分会 周江桥[2] Branch of Organ Transplantation,Chinese Medical Association;Zhou Jiangqiao(不详;Department of Organ Transplantation,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]不详 [2]武汉大学人民医院器官移植科,武汉430060

出　　处：《中华器官移植杂志》2024年第10期664-677,共14页Chinese Journal of Organ Transplantation

基　　金：国家自然科学基金(81870067、82170664)。

摘　　要：肾脏移植是治疗终末期肾脏病最有效的方式,随着移植技术水平的提高,选择再次肾脏移植的受者比例逐渐增多。再次肾脏移植需要面临诸多问题:避免首次移植肾失功的病因、手术难度增大、排斥反应风险增加、术后感染及远期并发症发生率增高、心理负担更重等。本指南围绕再次肾脏移植的适应证、手术方式、组织配型、感染预防及术后随访等方面进行推荐和说明,以期提高再次肾脏移植成功率,促进受者和移植肾的远期存活率。Kidney transplantation(KT)has been the most effective treatment of end-stage kidney disease(ESKD).With continuous improvements of transplantation technology,the proportion of patients choosing kidney re-transplantation(KR)is gradually rising.KR presents great challenges of avoiding the causes of initial graft failure,greater surgical complexity,higher risk of rejection,higher rates of postoperative infections and long-term complications,as well as heightened psychological burden.This guideline specified the indications,surgical techniques,tissue typing,postoperative follow-ups,infection prevention and other aspects of KR for boosting success rate of KR and promoting long-term survival of transplanted kidney allograft/recipient.

关 键 词：再次肾脏移植 肾脏移植 肾病复发 排斥反应 感染 供体特异性抗体 指南 

分 类 号：R699.2[医药卫生—泌尿科学]